Evaluation of the bioresistance profile of enterobacteria isolated from faeces of children with diarrhoea in the town of Koula-Moutou, Gabon: prospective study

Rolande Mabika Mabika, Sandrine Lydie Oyegue Liabagui, Franck Mounioko, Alain Souza, Jean Fabrice Yala

Corresponding author: Rolande Mabika Mabika, Laboratory of Molecular and Cellular Biology, Microbiology Team, Agrobiology Research Unit, Masuku University of Science and Technology, BP 067 Franceville, Gabon. rolandemabika@gmail.com

Received: 30 Jul 2020 - Accepted: 04 Sep 2022 - Published: 07 Oct 2022

Keywords: Panresistance, multiresistance, diarrhoea, enterobacteria, Gabon

Copyright: Rolande Mabika Mabika et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: Rolande Mabika Mabika et al. Evaluation of the bioresistance profile of enterobacteria isolated from faeces of children with diarrhoea in the town of Koula-Moutou, Gabon: prospective study. Pan African Medical Journal. 2022;43(63). 10.11604/pamj.2022.43.63.25276

Available online at: https://www.panafrican-med-journal.com/content/article/43/63/full

Evaluation of the bioresistance profile of enterobacteria isolated from faeces of children with diarrhoea in the town of Koula-Moutou, Gabon: prospective study

Rolande Mabika Mabika¹,², Sandrine Lydie Oyegue Liabagui², Franck Mounioko³, Alain Souza¹, Jean Fabrice Yala¹

¹Laboratory of Molecular and Cellular Biology, Microbiology Team, Agrobiology Research Unit, Masuku University of Science and Technology, BP 067 Franceville, Gabon, ²Laboratory of Research in Immunology, Parasitology and Microbiology, Regional Doctoral School of Central Africa in Tropical Infectiology, Masuku University of Science and Technology, Franceville, Gabon, ³Vector Ecology Laboratory, Tropical Ecology Research Institute, Libreville, Gabon

Corresponding author
Rolande Mabika Mabika, Laboratory of Molecular and Cellular Biology, Microbiology Team,
Agrobiology Research Unit, Masuku University of Science and Technology, BP 067 Franceville, Gabon

Abstract

Introduction: the emergence and expansion of multidrug resistance in Enterobacteriaceae responsible for various infections are increasing in the world. This study was designed to determine the phenotypic profiles of the resistance of enterobacteria strains isolated from the faeces of children with diarrhoeal diseases and to classify them according to the type of resistance. Methods: screening was carried out on 98 isolates divided into 2 groups: opportunistic pathogens and strict enteropathogens. Their sensitivity to 13 antibiotics was evaluated by the Mueller Hinton agar medium diffusion method. Results: a strong resistance to different classes of β-lactams was found in the strains, 74.0% (n=45) and 83.3% (n=31) for opportunists and enteropathogens, respectively. These strains were completely resistant to doxycycline and erythromycin (100%; n=98) for both types of bacteria. Opportunists and enteropathogens were 95.1% (n=58) and 94.6% (n=35) resistant to gentamicin, and 31.1% (n=19) and 35.1% (n=13) resistant to chloramphenicol, respectively. Similarly, the total resistance of strains was observed with ofloxacin and amounted to 98.4% (n=60) and 96.7% with levofloxacin and norfloxacin, respectively. The analysis of β-lactam resistance phenotypes revealed a dominance of the carbapenemase-producing strains (28.6%; n=28). However, 24.3% (n=9) of enteropathogens were pan-resistant versus 19.7% (n=12) for opportunists. Conclusion: the results of this study indicate a worrying high level of antibiotic resistance in enterobacteria which might tend towards total resistance.

Introduction

Diarrhoeal diseases due to their endemic nature, represent a public health problem in developing countries whose annual global incidence is estimated at 1.7 billion cases in children aged less than 5 years old [1,2]. In the majority of diarrhoeal cases of infectious origin, a variety of viral and bacterial pathogens are responsible and are most commonly found in children aged 0 to 5 years old [3,4]. The management of diarrhoeal diseases in African sub-Saharan countries is in most cases based on a probabilistic treatment without a prior research of the responsible agent mostly due to the absence or the obsolescence of the technical platforms of health structures [2,5]. This approach, to a lesser extent combined with the misuse of antibiotic prescriptions in some cases, is a risk factor for modifying the ecology of bacteria mainly in bacterial pathogens [6,7].

Enterobacteria, which are the most common causative agents of human infections, currently show a high antibiotic resistance panel due to the acquisition of resistance genes by this family [8,9]. Diarrhoeagenic Escherichia coli, Salmonella spp, Shigella spp and Yersinia spp are the major Enterobacteriaceae involved in diarrhoeal diseases and in recent years, an increase in antibiotic resistance used in treatment has been observed with the emergence of broad-spectrum β-lactamase-producing strains [10,11]. Furthermore, in the Sahel region, the emergence of strains resistant to amoxicillin, chloramphenicol, co-trimoxazole but also to cephalosporins and fluoroquinolones has been reported in the literature [12]. Moreover, with the release of enterobacteria from the producers of carbapenemases, the therapeutic capital is largely compromised [9,13-15]. This expansion and spread of enterobacteria resistance to almost all classes of antibiotics is currently a major problem in the management of these diseases in developing countries [15-17].

As of now, only few studies have investigated the molecular mechanisms of antimicrobial resistance among isolates isolated from patients in the sub-Saharan African region, particularly diarrhoeal patients, mainly due to the limited number of adequate infrastructures and researchers available on the continent [18]. Given this situation, it is very important to set up surveillance networks to gain
information on the spread of ESBLs and other resistance phenotypes in diarrhoeal pathogens to implement good clinical management during treatments.

It is in this context that this study aims to determine the antibiotic susceptibility profile of germs isolated from diarrhoeal faeces in children aged 0 to 5 years old in the town of Koula-Moutou and establish the phenotypes of resistance of circulating enterobacteria in it.

Methods

Study design and setting: all enterobacteria strain isolated from diarrhoeal faeces of children aged 0 to 5 years old hospitalized or received as outpatients were included in this study [19]. A total of 98 isolates from 11 genera were screened to assess their susceptibility to antibiotics. These strains were separated into two groups: 37 strict enteropathogens including Salmonella enterica, Salmonella Paratyphi A, Salmonella spp., Salmonella Typhi, Shigella sonnei, Shigella spp and Yersinia spp.; and 61 opportunistic enteropathogens (Citrobacter braakii, freundii and koseri, Escherichia vulneris, Enterobacter aerogenes and cloacae, Klebsiella oxytoca and pneumonae, Kluveyra spp, Pantoea spp, Raoultella ornithinolytica and terrigena).

Laboratory analysis: thirteen molecules belonging to five families of antibiotics (Bio-Rad, Marnes-la-Coquette, France and BBLTM Sensi-Disc) were used: for β-lactam, 3 penicillins including amoxicillin (AMX, 25 µg) (aminopenicillins), amoxicillin + clavulanic acid (AMC, 20/10 µg) and piperacillin + tazobactam (TZP, 100/10 µg); 2 cephalosporins including one of 3rd and one of 4th generation: ceftazidime (CAZ, 30µg), cefepime (FEP, 30µg) and a carbapenem, imipenem (IPM, 10µg). For families of aminoglycosides, macrolides, phenicolates and tetracyclines, the molecules were gentamicin (GME, 30 µg), erythromycin (ERY, 15 µg), chloramphenicol (CHL, 30 µg) and doxycycline (DOX, 30 µg), respectively. For the fluoroquinolone family, 3 molecules were tested: levofloxacin (LVX, 5µg), norfloxacin (NXN, 10µg) and ofloxacin (OFX, 5µg). These have not been tested on the different strict enteropathogenic strains in this study. The study of antibiotic susceptibility was carried out using the technique of diffusion of antibiotic discs in Mueller Hinton agar medium according to the Kirby-Bauer technique. Standard 0.5 McFarland inoculi was prepared in sterile physiological saline (0.9% NaCl) of 18-24 hours pure colonies. The interpretation of the results of the activity was based on the standards of the Antiibiogram Committee of the French Society (CASFM) recommendations 2019 v.2.0, except for erythromycin and doxycycline whose standards are in force and those of the CASFM 2013 and 2015, respectively. The identification of natural resistance phenotypes as well as the main mechanisms of acquired resistance to β-lactams from diarrhoeal fecal isolates, as well as the phenotypic classification of the different types of carbapenemases was performed by the interpretation of the antibiogram at specific ATB [20]. The strains were categorized as multidrug-resistant bacteria (MRB) for all those that had resistance to at least 3 antibiotic molecules belonging to the same family or different families [21]. Moreover, all those who presented a phenotype "resistant" to all 13 antibiotic molecules considered in this study were categorized as pan-resistant bacteria (PRB).

Statistical analysis: the chi-squared test was used to compare the different proportions of resistance with a threshold of significance set at 5%. "Intermediate" results were included in the "resistant" category. This test was performed using the R software v3.2.2.

Results

The screening of the strains with molecules belonging to the different classes of the β-lactam family and to the 4 antibiotic molecules belonging to the aminoglycoside, phenicolated, macrolide and tetracycline families was done on the two categories of isolated strains. Their phenotypic results are recorded in Table 1. The analysis of the
results shows a strong 95.9% (n=94) resistance to aminopenicillins (AMX) whose proportions are more or less similar to the two categories of strains with 96.7% (n=59) for opportunistic pathogens and 94.9% (n=35) for strict enteropathogens, respectively. In addition, the chi-squared test shows that there is a significant difference in behaviour depending on the bacterial groups (p < 0.0005). These percentages are slightly lower when these molecules are conjugated with the β-lactamase inhibitors: AMC (89.8%, n=88) and TZP (70.4%; n=69). Regarding the cephalosporin class, 91.8% (n=90) and 81.6% (n=80) of ceftazidime and cefepime, respectively, have high resistance levels. The opportunistic pathogens have resistance rates of 88.5% (n=54) and 70.5% (n=43), respectively, for ceftazidime and cefepime whereas those of enteropathogens are 97.3% (n=36) and 100% (n=37) for the same molecules. Also, a significant difference was recorded between these two groups for cefepime (p = 0.027). Finally, carbapenems remain the most active β-lactams with an average overall resistance rate of 36.7% (n=36), with the prevalences of 29.5% (n=18) and 48.6% (n=18) for opportunistic pathogens and strict enteropathogens (p < 0.0005), respectively.

These results show that the different isolates, both opportunistic pathogens and enteropathogens, have a total resistance to erythromycin (100%; n=98) and doxycycline (100%; n=98) without any significant difference between the two groups (p = 0.08). In addition, a strong resistance to gentamicin is also observed (94.9%; n=93). For chloramphenicol, an average resistance rate of 32.7% (n=32) was recorded with resistance rates of 31.1% (n=19) and 35.1% (n=13) for opportunistic pathogens and strict enteropathogens (p = 0.98), respectively (Table 1). The susceptibility of 61 isolates of opportunistic pathogens was assessed against 3 molecules of antibiotics belonging to the fluoroquinolone family (Table 2). A very high resistance is observed in opportunistic pathogens, generally without any significant difference with respect to the 3 molecules (p = 0.66). A 100% (n=61) resistance rate is reported for ofloxacin, 98.4% (n=60) for levofloxacin and 96.7% (n=59) for norfloxacin.

**Mechanisms of phenotypic resistance by the production of β-lactamase enzymes**

The Carbase resistance mechanism is the most common phenotype in enterobacterial strains, with a prevalence of 28.6% (n=28) (Table 3). The resistance rates are 21.3% (n=13) and 40.5% (n=15) for the opportunistic pathogen and strict enteropathogens groups, respectively. Moreover, class A/B is the most representative among the phenotypic classification of Carbase types with a frequency of 89.3% (n=87), of which 100.0% (n=61) and 80.0% (n=29) are found in the opportunists and in the strict enteropathogens, respectively. In contrast, Class D Carbase-positive strains have a low prevalence (10.7%; n=10). This phenotype is followed by the one associated with the combination of the production of an ESBL and/or a Case HP whose prevalence is 23.5% (n=23) and with 16.4% (n=10) of cases observed in opportunistic pathogens versus 35.1% (n=13) in strict enteropathogens. Strains of enterobacteria resistant to antibiotics by production Case BN have a prevalence of 20.4% (n=20) while those, a prevalence of 19.4% (n=19) is recorded for enterobacterial strains producing ESBL.

**Characterization of the type of resistance**

The results reveal that globally 78.6% (n=77) of the isolated enterobacteria strains are MRB and 21.4% (n=21) are PRB. Regarding opportunistic pathogens, only the *Citrobacter braakii, Citrobacter koseri, Enterobacter cloacae, Escherichia vulneris, Pantoea spp, Raoulletella terrigina* and *Serratia fonticola* species have a MRB profile, which represents 7 species out of 15 for this group. As for the group of strict enteropathogens, 3 species are only MRB: *Salmonella Paratyphi A, Shigella sonnei* and *Yersinia pestis*. 
Discussion

The objective of this study was to establish the antibiotic susceptibility profile of opportunistic Enterobacteriaceae and strict pathogens associated with diarrhoea cases in children in the city of Koula-Moutou in Gabon. Enterobacteria isolated from diarrhoeal faeces have high levels of resistance to the different families (β-lactam, quinolones) of tested antibiotics, among which are molecules prescribed by health personnel in case of suspicion of infectious diarrhoea. However, for the molecules of the last therapeutic lines (carbapenems) and also for chloramphenicol, low rates of resistance are recorded suggesting in particular their weak utilization or the installation of the mechanisms of resistance. The analysis of β-lactam resistance phenotypes revealed a dominance of the carbapenemase-producing strains and those producing the ESBL/Case. According to the different bacterial groups, the strains present have more of a multiresistant bacterial character despite the low rate of the so-called pan-resistant bacteria recorded.

The resistance profiles recorded in this study corroborate those of the many studies concerning enterobacteria that are involved in many human infections [22,23]. The high levels of β-lactam resistance recorded in this work are similar to those reported by other studies [24,25]. Indeed, for opportunistic pathogens, AMX resistance levels belonging to the aminopenicillin class with ampicillin are very high. These results are similar to those recorded against AMP in the studies of Azimi et al. in Teheran and Monira et al. in Bangladesh [25,26]. Similarly, the high AMC resistance rates obtained in this study are comparable to those of the study by Azimi et al. [25]. Compared to enteropathogens, Salmonella isolates also show high rates of resistance to amoxicillin alone or with added clavulanic acid. These rates are comparable to those reported by Randrianirina et al. (35.7%) in Madagascar [24]. Furthermore, resistance prevalences similar to other studies were recorded for strains of Shigella spp, for the aminopenicillin class [27]. These high levels of resistance to aminopenicillins, in particular AMC, could be explained by current practices in the hospital environment because this molecule is more commonly prescribed in the treatment of various conditions [2,22].

Regarding the cephalosporins, the resistance rates found in this study are significantly higher than those of other studies for both opportunistic Enterobacteriaceae and enteropathogens [12,24,26]. In developing countries, the use of antibiotics for prophylaxis and therapy is widespread, particularly in the treatment of infantile bacterial diarrhoeal diseases in addition to urinary tract infections [2,22]. These practices would contribute to the selection of chromosomal and plasmidic hyperproductive mutants of cephalosporinases during treatment [9,28]. Indeed, this phenomenon is particularly found in Enterobacter cloacae, aerogenes, Citrobacter freundii, Klebsiella spp and Salmonella spp [9] species as is the existence of the phenomenon of cross-transmission of resistance genes. This is particularly observed in enterobacteria and can explain the high levels of resistance in this study. In addition, the global ESBL, which are third-generation β-lactamases that hydrolyze cephalosporins and aztreonam, is responsible for increasing the resistance of these strains to the majority of β-lactams [29,30] including cephalosporins.

Regarding the class of penems, an overall resistance of 36.7% against IMP is obtained, with a rate of 27.9% for opportunists. This prevalence is similar to the one obtained by Azimi et al. Their work has indeed recorded resistance rates of 18.5% and 53.6% for Klebsiella spp and Citrobacter spp, respectively, comparable to those of our study estimated at 16.5% for Klebsiella spp and 33.3% for Citrobacter spp. In Niger and Morocco, isolated enteropathogens had low resistance rates to IMP of 0%, 0%, and 0%; and 0%, 0% and 1.4% for Salmonella spp, Shigella spp and diarrhoeagenic Escherichia coli strains [12,21], respectively. In our study these resistance rates are 50.1% and 16.7%.
for *Salmonella* spp and *Shigella*, respectively. These obtained prevalences could be the result of the dissemination of carbapenemase-producing strains which are described as epidemiogenic [13,31]. Or in this case, the association of a decrease in porin (alteration of membrane permeability) with the production of an ESBL or Case [14,29] could possibly be one of the mechanisms developed by these isolates which would explain the prevalence of resistance to this antibiotic.

The strong resistance to quinolones in this study highlights the spread of resistant enterobacteria to this antibiotic family, particularly in *E. coli*, *Salmonella* spp and *Shigella* spp [11,32,33]. Moreover, the prophylactic treatments have been refocused on β-lactams and fluoroquinolones for bacterial diarrhoeal pathologies [34], this therapeutic alternative could have contributed to the expansion of multiresistant strains against these molecules in enterobacteria. Based on these results, it appears that the spectrum of active molecules against enterobacteria in the town of Koula-Moutou is very limited and raises a real public health problem in the management of diarrhoeal patients. The different resistance profiles to the different families of antibiotics recorded in this study corroborate the expansion of the resistance phenomenon of enterobacteria, which is mainly due to the production of ß-lactamase enzymes, in particular the production of penicillinases, broad-spectrum ß-lactamases (ESBL), chromosomal or plasmidic cephalosporinases (Case) and carbapenemases [30,35]. Obviously, to survive drug pressure due to antibiotics, bacteria have developed survival strategies by diversifying their acquired resistance mechanisms, mainly through the acquisition of mobile genetic elements [9,26], in addition to regulatory systems that can sometimes control the expression of natural ß-lactamases [20]. Thus, 23.5% of the strains studied produce an ESBL associated with the production of a Case, whose prevalence is higher than that obtained in Algeria (14.3%) [6] and in the Netherlands (4.5%) [36]. In addition, 19.4% of isolated enterobacteria are ESBL producers, with a high frequency compared to that found by Chervet et al. in Paris (4%) [23], lower than that obtained by Yala et al. in Gabon (51%) [37] and on the African continent (77.8%) [38]. In this study, 20.4% of isolates produce Case, which would increase the resistance potential of these isolates, undoubtedly explaining the high levels of resistance observed in this study. Their isolation frequency is higher than that obtained by van Den Bunt et al. in the Netherlands, which was 0.2% for children under 5 years old and 0.4% for the overall population [39]. Furthermore, 28.6% of *Enterobacteriaceae* produce carbapenemases in this study, whose prevalence is lower than that obtained by Mabika Mabika et al. (2019) [40]. Ultimately, the mechanism of enzyme production in antibiotic resistance is widespread and diversified within the enterobacterial strains studied.

At present, the global epidemiological context is marked by the emergence of MRB dominated by Gram-negative bacteria whose main representatives are *Enterobacteriaceae*, *Pseudomonas aeruginosa* and *Acinetobacter* which are resistant to large classes of antibiotics, sometimes cross-referenced [41,42]. The results of this study corroborate in particular the observations reported in the literature. Indeed, an overall prevalence of MRB enterobacteria isolates estimated at 78.6% is recorded with a frequency higher than that obtained in Morocco (47.7%) [21]. This high prevalence of MRB could be explained and confirmed by the production of β-lactamases of the ESBL, Case and carbapenemase type by the isolates which give them resistance to β-lactams and to the families of antibiotics tested as well [41]. Genes coding for these enzymes are usually located on plasmids often associated with other resistance genes to other classes of antibiotics [9], as well as other mobile genetic elements (transposons, class 1 and 2 integrations) [26]. Consequently, the genetic multiplicity of resistance on these different elements, and the rapid adaptability could contribute to the emergence of mutants resistant to all the usual classes of antibiotics, possibly explaining the 21.4% of the pan-resistant isolates obtained in this study.
Moreover, it has been reported in the literature that commensal strains may constitute reservoirs of antibiotic resistance in the community [26]. Although the mechanism of resistance was identified only phenotypically in this study, for the 19.7% of isolated PRB opportunists, a frequency of 21.3% of EPC is identified, arguably in favour of BHRe cases. Our prospective study clearly established the emergence of diarrhoeal bacterial strains in several families of first-line antibiotics phenotypically. However, one of the main limitations of this study is the lack of molecular characterization of resistance genes on our strains that would have better established the risk of dissemination in our country.

**Conclusion**

This study highlights the very high prevalence of *Enterobacteriaceae* isolated from diarrhoeal faeces against antibiotics commonly used in the treatment of diarrhoeal diseases in Gabon. Although the majority of these strains are multiresistant, carbapenems and chloramphenicol still remain the most active molecules in most of them despite the resistance observed in rare cases. Furthermore, this study also reveals a low average proportion of carbapenem-resistant strains, although the combination of ESBL with a cephalosporinase was the most common phenotype in this study. Specific tests should be routinely performed to better characterize these β-lactamase resistance phenotypes, particularly regarding carbapenem resistance.

**What is known about this topic**

- The emergence of antibiotic-resistant strains in diarrhoeal isolates;
- The risk of increasing bacterial resistance through the practice of using empirical treatments.

**What this study adds**

- Profiles of resistance mechanisms circulating in the said city and by extension at the national level.

**Competing interests**

The authors declare no competing interests.

**Authors' contributions**

Jean Fabrice Yala, Alain Souza, Rolande Mabika Mabika conceived and designed the experiments. Jean Fabrice Yala and Rolande Mabika Mabika performed the experiments. Jean Fabrice Yala, Rolande Mabika Mabika and Franck Mounioko analyzed the data. Rolande Mabika Mabika, Sandrine Lydie Oyegue Liabagui, Franck Mounioko, Alain Souza, and Jean Fabrice Yala wrote the original manuscript. All the authors wrote, reviewed, edited, read and approved the final version of the manuscript.

**Acknowledgments**

The authors are grateful to the bacteriology-immunology team at LABMC for providing the bacteria necessary for this study and their availability.

**Tables**

| Table 1: resistance profiles of enterobacteria to β-lactams and 4 antibiotics belonging to various families |
| Table 2: resistance profile of enterobacteria isolated from quinolone diarrhoea |
| Table 3: phenotype of resistance of enteric strains to β-lactams |

**References**

1. OMS. Maladies diarrhéiques. Cited 2017 May 02
2. Ateudjieu J, Bita’a Beyala L, Guenou E, Chebe AN, Chukuwchindun BA, Goura AP et al. Profil et antibiosensibilité des bactéries pathogènes associées aux diarrhées chez les patients consultants à l’Hôpital Régional Annexe de Kousseri, Extrême-Nord Cameroun. Pan Afr Med J. 2018;29(170): 1-1. PubMed | Google Scholar

3. Pathania M, Rathaur VK, Jayara A, Yadav N. Clinical Study of Acute Childhood Diarrhoea Caused by Bacterial Enteropathogens. J Clin Diagnostic Res. 2014;8(5): 1-5. PubMed | Google Scholar

4. Seck N, Basse I, Faye PM, Boiro D, Thiam L, Diagne-Geuye NR et al. Prise en charge de la diarrhée aiguë bactérienne à l’hôpital pour enfants de Diamniadio (HED), Sénégal. J Pediatri Pueric. 2018;1-6. Google Scholar

5. Gendre D, Cohen R. Diarrhées bactériennes et antibiotiques: les recommandations européennes. Arch Pédiatrie. 2008;15: 593-596. Google Scholar

6. Djahida S, Imane S, Mourad D. Résistance aux antibiotiques des entérobactéries au niveau du CHU de Sidi Bel Abbes (Algérie). Microbiol Hyg Alim. 2011;23(67): 37-41. Google Scholar

7. Koko J, Ategbo S, Gahouma D. Epidémiologie des diarrhées aiguës bactériennes de l’enfant à Libreville, Gabon. Arch Pédiatrie. 2013;XXX(1): 1-2. Google Scholar

8. Nordmann P, Gniadkowski M, Giske CG, Poirel L, Woodford N, Miriagou V. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2012;18(5): 432-43. PubMed | Google Scholar

9. Tani ZBA, Arlet G. Actualité de la résistance aux antibiotiques chez les bacilles Gram-negative en Algérie. Pathol Biol. 2014;62: 169-178. Google Scholar

10. Mosquito S, Ruiz J, Pons MJ, Duranda D, Barletta F, Ochoa TJ. Molecular mechanisms of antibiotic resistance in diarrhoeagenic Escherichia coli isolated from children Susan. Int J Antimicrob Agents. 2012;40(57758): 544-548. Google Scholar

11. Ranjbar R, Behnood V, Memariani H, Najafi A, Moghboli M, Mammina C. Molecular characterisation of quinolone-resistant Shigella strains isolated in Tehran, Iran. J Glob Antimicrob Resist. 2016;5: 26-30. PubMed | Google Scholar

12. Langendorf C, Le Hello S, Mounouni A, Gouali M, Mamaty A-A, Grais RF et al. Enteric Bacterial Pathogens in Children with Diarrhoea in Niger: Diversity and Antimicrobial Resistance. PLoS One. 2015;10(3): 1-18. PubMed | Google Scholar

13. Abbas M, Cherkaooui A, Fankhauser A, Schrenzel J, Harbarth S. Carbapénèmes: implications cliniques et épidémiologiques pour la Suisse. Rev Med Suisse. 2012;8(338): 882-4, 886-889. PubMed | Google Scholar

14. Poirel L, Dortet L, Nordmann P. Epidémiologie des carbapénèmes. Curr Epidemiol carbapenemases. 2013;28(4): 124-127. Google Scholar

15. Ouedraogo AS, PierreH J, Banuls AL, Ouédraogo R, Godreuil S. Émergence et diffusion de la résistance aux antibiotiques en Afrique de l'Ouest: facteurs favorisants et évaluation de la menace. Med Sante Trop. 2017;27: 147-154. Google Scholar

16. Beyene G, Nair S, Asrat D, Mengistu Y, EngersJ H, Wain J. Multidrug-resistant Salmonella concord is a major cause of salmonellosis in children in. J Infect Dev Ctries. 2011;5(1): 23-33. PubMed | Google Scholar

17. Falagas ME, Karageorgopoulos DE, Nordmann P. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiol. 2011;6(6): 653-666. PubMed | Google Scholar

18. Mandomando I, Jaintilal D, Pons MJ, Vallès X, Espasa M, Mensa L et al. Antimicrobial Susceptibility and Mechanisms of Resistance in Shigella and Salmonella Isolates from Children under Five Years of Age with Diarrhoea in Rural Mozambique. Antimicrob Agents Chemother. 2009;53(6): 2450-2454. PubMed | Google Scholar
Mabika Mabika R, Oyegue-Liabagui SL, Mounioko F, Dibakou SE, Mongo Delis A, Moussavou MG et al. Etiology and biodistribution of enterobacteria and parasites, among children under 5 years old with diarrhoea in East-Central Gabon. Ann Clin Med Microbiol. 2021;5(1): 1-13. Google Scholar

Robin F, Gibold L, Bonnet R. Résistances naturelles et acquises aux β-lactamines chez les entérobactéries: comment les identifier en pratique quotidienne. Rev Francoph des Lab. 2012;445: 47-58. Google Scholar

Benmessaoud R, Nezha M, Moraleda C, Jroundi I, Houssain T, Pons MJ et al. Antimicrobial resistance levels among diarrhoeagenic microorganisms recovered from children under-5 with acute moderate-to-severe diarrhoea in Rabat, Morocco. J Glob Antimicrob Resist. 2016;7: 34-36. Google Scholar

Okalla Ebongue C, Tsiazok MD, Nda Mefo’o JP, Ngaba GP, Beyiha G, Adiogo D. Evolution de la résistance aux antibiotiques des entérobactéries isolées à l’Hôpital Général de Douala de 2005 à 2012. Pan Afr Med J. 2015;20(227): 1-11. PubMed | Google Scholar

Chervet D, Lortholary O, Zahar J, Dufougeray A, Pilmis B, Partouche H. Antimicrobial resistance in community-acquired urinary tract infections in Paris in 2015. Med Mal Infect. 2017;5-9. Google Scholar

Randrianirina F, Ratsima EH, Ramparany L, Randremanana R, Rakotonirina HC, Andriamanantena T et al. Antimicrobial resistance of bacterial enteropathogens isolated from stools in Madagascar. BMC Infect Dis. 2014;14(104): 1-7. PubMed | Google Scholar

Azimi T, Maham S, Fallah F, Azimi L, Gholinejad Z. Evaluating the antimicrobial resistance patterns among major bacterial pathogens isolated from clinical specimens taken from patients in Mo fi d Children’s Hospital, Tehran, Iran: 2013-2018. Infect Drug Resistance. 2019;12: 2089-102. Google Scholar

Monira S, Shabnam SA, Ali SI, Sadique A, Johura FT, Rahman KZ et al. Multi-drug resistant pathogenic bacteria in the gut of young children in Bangladesh. Gut Pathog. 2017;9(19): 4-11. PubMed | Google Scholar

Qu M, Lv B, Zhang X, Yan H, Huang Y, Qian H et al. Prevalence and antibiotic resistance of bacterial pathogens isolated from childhood diarrhoea in Beijing, China (2010 - 2014). Gut Pathog. 2016;8(31): 1-9. PubMed | Google Scholar

Conen A, Frei R, Adler H, Dangel M, Fux CA. Microbiological Screening Is Necessary to Distinguish Carriers of Plasmid-Mediated AmpC Beta-Lactamase-Producing Enterobacteriaceae and Extended-Spectrum Enterobacteriaceae because of Clinical Similarity. PLoS One. 2015;10(3): 1-14. PubMed | Google Scholar

Baran I, Aksu N. Phenotypic and genotypic characteristics of carbapenem-resistant Enterobacteriaceae in a tertiary level reference hospital in Turkey. Ann Clin Microbiol Antimicrob. 2016;(5): 1-11. PubMed | Google Scholar

Haller L, Chen H, Ng C, Hoang T, Hsien T, Barkham T et al. Occurrence and characteristics of extended-spectrum β-lactamase and carbapenemase-producing bacteria from hospital effluents in Singapore. Sci Total Environ. 2018;615: 1119-1125. PubMed | Google Scholar

Sheikh AF, Moosavian M, Abdi M, Heidary M, Shahi F, Jomehzadeh N et al. Prevalence and antimicrobial resistance of Shigella species isolated from diarrhoeal patients in Ahvaz, southwest Iran. Infect Drug Resistance. 2019;12(249-253): 249-253. PubMed | Google Scholar

Ranjar R, Tolon SS, Sami M, Golmohammadi R. Detection of plasmid-mediated qnr genes among the clinical quinolone-resistant Escherichia coli strains isolated in Tehran, Iran. Open Microbiol J. 2018;12: 248-253. PubMed | Google Scholar
33. Schau J, Sunde M, Ulstad CR, Norström, M, Wester A, Urdahl AM. Occurrence and characterization of quinolone-resistant Escherichia coli from Norwegian turkey meat and complete sequence of an IncX1 plasmid encoding qnrS1. PLoS One. 2019;14(3): 1-16. Google Scholar

34. Sánchez-Vargas FM, Abu-el-haija MA, Gomez-Duarte OG. Salmonella infections: An update on epidemiology, management, and prevention. Travel Med Infect Dis. 2011;9: 263-277. PubMed | Google Scholar

35. Meini S, Tascini C, Cei M, Sozio E, Maria G. AmpC --lactamase-producing Enterobacterales: what a clinician should know. Infection. 2019;0(0): 1-13. PubMed | Google Scholar

36. Wielders CCH, Van Hoek AHAM, Hengeveld PD, Veenman C, Dierikx CM, Zomer TP et al. Enterobacteriaceae among the general population in a livestock-dense area. Clin Microbiol Infect. 2017;23(2): 120.e1-120.e8. PubMed | Google Scholar

37. Yala J, Mabika RM, Bisseye C, Kenguele H, Kama EM, Dikoumba AC et al. Phenotypic and genotypic characterization of Enterobacteriaceae (ESBLE) in patients attending Omar Bongo Ondimba military hospital at Libreville. Open Journal of Medical Microbiology. 2016;4(6): 944-949. Google Scholar

38. Sangare SA, Maiga AI, Camara N, Savadogo S, Diallo S, Bougouodo F et al. Prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolated from blood cultures in Africa. Med Mal Infect. 2015;45(9): 374-382. PubMed | Google Scholar

39. Van Den Bunt G, Liakopoulos A, Mevius DJ, Geurts Y, Fluit AC, Bonten MJM et al. ESBL / AmpC-producing Enterobacteriaceae in households with children of preschool age: prevalence, risk factors and co-carriage. J Antimicrob Chemother. 2017;72: 589-595. PubMed | Google Scholar

40. Mabika Mabika R, Oyegue Llabagui SL, Mounioko F, Moussavou M-G, Affiri Odzame J, Souza A et al. Study of the sensitivity to carbapenems in the Escherichia coli isolated from childhood diarrhoea at the Paul Moukambi Hospital Center of Koula-Moutou. Int J Innov Sci Res. 2019;8(6): 1411-1417. Google Scholar

41. De Vallière S. Multidrug-resistant bacteria and travel. Rev Med Suisse. 2017;561(13): 944-947. PubMed | Google Scholar

42. Poissy J, Parmentier-Decrucq E, Thieffry C, Duburcq T, Mathieu D. «Nouvelles» molécules anti-infectieuse: quelle place en médecine intensive/réanimation pour ceftolozane-tazobactam et la témocilline? Méd Intensive Réa. 2017;26: 224-232. Google Scholar
### Table 1: Resistance profiles of enterobacteria to β-lactams and 4 antibiotics belonging to various families

| Names of bacterial strains | N  | AMX  | AMC  | TAZ  | CAZ  | FEP  | IMP  | GME  | CHL  | ERY  | DOX  |
|---------------------------|----|------|------|------|------|------|------|------|------|------|------|
|                           |    | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
| **Opportunistic pathogens** |    | (%)  | (%)  | (%)  | (%)  | (%)  | (%)  | (%)  | (%)  | (%)  | (%)  |
| Citrobacter braakii       | 1  | 1 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 1 (100.0) |
| Citrobacter freundii      | 1  | 1 (100.0) | 1 (100.0) | 1 (100.0) | 0 (0.0) | 0 (0.0) | 1 (100.0) | 1 (100.0) | 1 (100.0) | 1 (100.0) |
| Citrobacter koseri        | 1  | 1 (100.0) | 1 (100.0) | 1 (100.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 1 (100.0) |
| Enterobacter aerogenes    | 5  | 5 (100.0) | 4 (80.0) | 4 (80.0) | 2 (40.0) | 2 (40.0) | 5 (100.0) | 3 (60.0) | 5 (100.0) | 5 (100.0) |
| Enterobacter cloaceae     | 2  | 2 (100.0) | 2 (100.0) | 2 (100.0) | 0 (0.0) | 2 (100.0) | 1 (50.0) | 2 (100.0) | 2 (100.0) |
| Escherichia vulneris      | 2  | 2 (100.0) | 2 (100.0) | 2 (100.0) | 0 (0.0) | 2 (100.0) | 2 (100.0) |
| Klebsiella oxytoca        | 3  | 3 (100.0) | 2 (66.7) | 3 (100.0) | 3 (100.0) | 1 (33.3) | 2 (66.7) | 1 (33.3) | 3 (100.0) |
| Klebsiella pneumoniae     | 3  | 3 (75.0) | 3 (75.0) | 3 (75.0) | 4 (100.0) | 4 (100.0) | 3 (75.0) | 4 (100.0) | 1 (25.0) | 4 (100.0) | 4 (100.0) |
| Kluyvera spp              | 5  | 5 (100.0) | 5 (100.0) | 3 (60.0) | 5 (100.0) | 5 (100.0) | 1 (20.0) | 5 (100.0) | 5 (100.0) |
| Pantoea spp               | 1  | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 1 (100.0) |
| Raoultella ornithinolytica | 21 | 21 (100.0) | 17 (81.0) | 16 (76.2) | 21 (100.0) | 15 (71.4) | 5 (23.8) | 19 (90.5) | 4 (19.0) | 21 (100.0) | 21 (100.0) |
| Raoultella terrigina      | 4  | 4 (100.0) | 4 (100.0) | 2 (50.0) | 4 (100.0) | 4 (100.0) | 2 (50.0) | 4 (100.0) |
| Serratia fonticola        | 5  | 5 (100.0) | 4 (80.0) | 4 (80.0) | 2 (40.0) | 2 (40.0) | 0 (0.0) | 5 (100.0) | 1 (20.0) | 5 (100.0) | 5 (100.0) |
| Serratia liquefaciens     | 2  | 2 (100.0) | 2 (100.0) | 1 (50.0) | 2 (100.0) | 0 (0.0) | 1 (50.0) | 2 (100.0) | 2 (100.0) |
| Serratia odorifera 1      | 4  | 3 (75.0) | 3 (75.0) | 3 (75.0) | 2 (50.0) | 1 (25.0) | 4 (100.0) | 2 (50.0) | 4 (100.0) |
| **Total**                | 61 | 59 (96.7) | 54 (88.5) | 44 (72.1) | 54 (88.5) | 43 (70.5) | 17 (27.9) | 58 (95.1) | 19 (31.1) | 61 (100.0) | 61 (100.0) |
| **Enteric pathogens**     |    |      |      |      |      |      |      |      |      |      |      |
| Salmonella enterica       | 6  | 6 (100.0) | 6 (100.0) | 3 (50.0) | 6 (100.0) | 6 (100.0) | 4 (66.7) | 6 (100.0) | 2 (33.3) | 6 (100.0) | 6 (100.0) |
| Salmonella Paratyphi A    | 3  | 3 (100.0) | 3 (100.0) | 3 (100.0) | 3 (100.0) | 3 (100.0) | 0 (0.0) | 3 (100.0) | 1 (33.3) | 3 (100.0) | 3 (100.0) |
| Salmonella spp            | 17 | 15 (88.2) | 15 (88.2) | 11 (64.7) | 17 (100.0) | 17 (100.0) | 10 (58.8) | 16 (94.1) | 5 (29.4) | 17 (100.0) | 17 (100.0) |
| Salmonella Typhi          | 4  | 4 (100.0) | 3 (75.0) | 3 (75.0) | 3 (75.0) | 4 (100.0) | 3 (75.0) | 4 (100.0) | 1 (25.0) | 4 (100.0) | 4 (100.0) |
| Shigella sonnei           | 2  | 2 (100.0) | 2 (100.0) | 2 (100.0) | 2 (100.0) | 0 (0.0) | 2 (100.0) | 0 (0.0) | 2 (100.0) |
| Shigella spp              | 3  | 3 (100.0) | 3 (100.0) | 3 (100.0) | 3 (100.0) | 3 (100.0) | 1 (33.3) | 2 (66.7) | 2 (66.7) | 3 (100.0) | 3 (100.0) |
| Yersinia pestis           | 2  | 2 (100.0) | 2 (100.0) | 0 (0.0) | 2 (100.0) | 2 (100.0) | 0 (0.0) | 2 (100.0) | 2 (100.0) |
| **Total**                | 37 | 35 (94.6) | 34 (91.9) | 25 (67.6) | 36 (97.3) | 37 (100.0) | 18 (48.6) | 35 (94.6) | 13 (35.1) | 37 (100.0) | 37 (100.0) |
| **Global Percentage of resistance** | 98 | 94 (95.9) | 88 (89.8) | 69 (70.4) | 90 (91.8) | 80 (81.6) | 36 (36.7) | 93 (94.9) | 32 (32.7) | 98 (100.0) | 98 (100.0) |

**AMX:** amoxicillin; **AMC:** amoxicillin + clavulanic acid; **TAZ:** piperacillin / tazobactam; **CAZ:** ceftazidime; **FEP:** cefepime; **IMP:** imipenem; **GME:** gentamicine; **CHL:** chloramphénicol; **ERY:** érythromycine; **DOX:** doxycycline.
### Table 2: Resistance profile of enterobacteria isolated from quinolone diarrhoea

| Names of bacterial strains         | N  | LVX n (% I/R) | OFX n (% I/R) | NXN n (% I/R) |
|-----------------------------------|----|---------------|---------------|---------------|
| **Opportunistic pathogens**       |    |               |               |               |
| Citrobacter braakii               | 1  | 1 (100,0)     | 1 (100,0)     | 1 (100,0)     |
| Citrobacter freundii              | 1  | 1 (100,0)     | 1 (100,0)     | 1 (100,0)     |
| Citrobacter koseri                | 1  | 1 (100,0)     | 1 (100,0)     | 1 (100,0)     |
| Enterobacter aerogenes            | 5  | 5 (100,0)     | 5 (100,0)     | 5 (100,0)     |
| Enterobacter cloacae              | 2  | 2 (100,0)     | 2 (100,0)     | 2 (100,0)     |
| Escherichia vulneris              | 2  | 2 (100,0)     | 2 (100,0)     | 2 (100,0)     |
| Klebsiella oxytoca                | 3  | 2 (66,7)      | 3 (100,0)     | 2 (66,7)      |
| Klebsiella pneumoniae             | 4  | 4 (100,0)     | 4 (100,0)     | 4 (100,0)     |
| Kluvyvera spp                     | 5  | 5 (100,0)     | 5 (100,0)     | 5 (100,0)     |
| Pantoea spp                       | 1  | 1 (100,0)     | 1 (100,0)     | 1 (100,0)     |
| Raoultella ornitholytica          | 21 | 21 (100,0)    | 21 (100,0)    | 20 (95,2)     |
| Raoultella terrigina              | 4  | 4 (100,0)     | 4 (100,0)     | 4 (100,0)     |
| Serratia fonticola                | 5  | 5 (100,0)     | 5 (100,0)     | 5 (100,0)     |
| Serratia liquefaciens             | 2  | 2 (100,0)     | 2 (100,0)     | 2 (100,0)     |
| Serratia odorifera 1              | 4  | 4 (100,0)     | 4 (100,0)     | 4 (100,0)     |
| **Global Percentage of resistance** | 61 | 60 (98.4)     | 61 (100.0)    | 59 (96.7)     |

LVX: levofloxacin; OFX: ofloxacin; NXN: norfloxacin
### Table 3: phenotype of resistance of enteric strains to β-lactams

| Names of bacterial strains          | Pase | BLSE  | Case BN     | BLSE and/or CaseHP | Carbase |
|-------------------------------------|------|-------|-------------|-------------------|---------|
|                                     | N    | n (%) | n (%)       | n (%)             | n (%)   |
| **Opportunistic pathogens**         |      |       |             |                   |         |
| Citrobacter braakii                 | 1    | -     | -           | 1 (100.0)         |         |
| Citrobacter freundii                | 1    | -     | -           | 1 (100.0)         |         |
| Citrobacter koseri                  | 1    | -     | -           |                   | 1(100.0)         |
| Enterobacter aerogenes              | 5    | -     | -           | 3 (40.0)          | 2 (60.0)         |
| Enterobacter cloacae                | 2    | -     | -           | 2 (100.0)         |         |
| Escherichia vulneris                | 2    | -     | -           | 1 (50.0)          | 1 (50.0)         |
| Klebsiella oxytoca                  | 3    | -     | 1 (33.3)    |                   | 2 (66.7)         |
| Klebsiella pneumoniae               | 4    | 1 (25.0) | 1 (25.0) | - | 2 (50.0) |
| Klyvera spp                         | 5    | -     | 4 (80.0)    | -                 | 1 (20.0)) |
| Pantoea spp                         | 1    | 1 (100.0) | -     | - | 1 (100.0) |
| Raoultella ornithinolytica          | 21   | 3 (14.3) | 4 (19.0) | 5 (23.8) | 6 (28.6) | 3 (14.3) |
| Raoultella terrigina                | 4    | -     | 2 (50.0)    | -                 | 2 (50.0) |
| Serratia fonticola                  | 5    | -     | 1 (20.0)    | 3 (60.0)          | 1 (20.0) |
| Serratia liquefaciens               | 2    | -     | -           | 1 (50.0)          | 1 (50.0) |
| Serratia odorifer 1                 | 4    | 1 (25.0) | -     | 2 (50.0) | 1 (25.0) |
| **Total**                           | 61   | 6 (9.8) | 14 (23.0) | 18 (29.5) | 10 (16.4) | 13 (21.3) |
| **Enteropathogens**                 |      |       |             |                   |         |
| Salmonella enterica                 | 6    | -     | -           | -                 | 2 (33.3) | 4 (66.7) |
| Salmonella Paratyphi A              | 3    | -     | -           | -                 | 3 (100.0) |         |
| Salmonella spp                      | 17   | 2 (11.8) | 3 (17.6) | 1 (5.9) | 3 (17.6) | 8 (47.1) |
| Salmonella Typhi                    | 4    | -     | -           | 1 (25.0)          | - | 3 (75.0) |
| Shigella sonnei                     | 2    | -     | 2 (100.0)   | -                 | -         |
| Shigella spp                        | 3    | -     | -           | -                 | 3 (100.0) |
| Yersinia pestis                     | 2    | -     | -           | -                 | 2 (100.0) |
| **Total**                           | 37   | 2 (5.4) | 5 (13.5) | 2 (5.4) | 13 (35.1) | 15 (40.5) |
| **Global Percentage of resistance**| 98   | 8 (8.2) | 19 (19.4) | 20 (20.4) | 23 (23.5) | 28 (28.6) |

**Pase**: broad spectrum penicillinases; **Case BN**: low level cephalosporinase; **Case HP**: cephalosporinase High level; **ESBL**: broad-spectrum β-lactamases; **Carbase**: carbapenemases